Company intelligence / Profile preview

Mavupharma

Kirkland, Washington, United States

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Mavupharma’s lead asset, MAVU-104, is an orally available, first-in-class small molecule ENPP1 inhibitor designed to enhance STING pathway activation. Preclinical data suggested unique advantages over injectable STING agonists, but no public clinical trial results were reported prior to acquisition. Pipeline now integrated within AbbVie

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Major investor partnerships (Frazier Healthcare Partners, Alpine BioVentures)no major pharma co-development reported pre-acquisition

Beyond the preview

Go deeper on Mavupharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mavupharma.

Explore the full profile